Objective: Systemic administration of anti-Vascular Endothelial Growth Factors (an-ti-VEGFs) has been associated with severe cardiovascular adverse events in oncologic patients. The purpose of this pilot study is to evaluate the short-term effect of a single intravitreal injection of aflibercept on biomarkers related to increased risk of cardiovascular disease. Patients and Methods: Forty-seven treatment na & iuml;ve patients with neovascular age-related macular degeneration in one eye were enrolled in the study. The patients underwent treatment with one in-travitreal injection of aflibercept in the affected eye. Laboratory biomarkers of cardiovascular dis-ease were evaluated before the first intravitreal injection of aflibercept and at 7 and 30 days after aflibercept administration. More precisely, we evaluated the levels of homocysteine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and C-reactive protein. Results: There was not any statistically significant change in the levels of the evaluated parameters up to one month after the first intravitreal injection of aflibercept. Conclusion: According to our study, the administration of a single dose of aflibercept in eyes with neovascular age-related macular degeneration does not seem to affect the evaluated biomarkers that are related to cardiovascular disease. Objective: Systemic administration of anti-Vascular Endothelial Growth Factors (an-ti-VEGFs) has been associated with severe cardiovascular adverse events in oncologic patients. The purpose of this pilot study is to evaluate the short-term effect of a single intravitreal injection of aflibercept on biomarkers related to increased risk of cardiovascular disease. Patients and Methods: Forty-seven treatment na & iuml;ve patients with neovascular age-related macular degeneration in one eye were enrolled in the study. The patients underwent treatment with one in-travitreal injection of aflibercept in the affected eye. Laboratory biomarkers of cardiovascular dis-ease were evaluated before the first intravitreal injection of aflibercept and at 7 and 30 days after aflibercept administration. More precisely, we evaluated the levels of homocysteine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and C-reactive protein. Results: There was not any statistically significant change in the levels of the evaluated parameters up to one month after the first intravitreal injection of aflibercept. Conclusion: According to our study, the administration of a single dose of aflibercept in eyes with neovascular age-related macular degeneration does not seem to affect the evaluated biomarkers that are related to cardiovascular disease. Objective: Systemic administration of anti-Vascular Endothelial Growth Factors (an-ti-VEGFs) has been associated with severe cardiovascular adverse events in oncologic patients. The purpose of this pilot study is to evaluate the short-term effect of a single intravitreal injection of aflibercept on biomarkers related to increased risk of cardiovascular disease. Patients and Methods: Forty-seven treatment na & iuml;ve patients with neovascular age-related macular degeneration in one eye were enrolled in the study. The patients underwent treatment with one in-travitreal injection of aflibercept in the affected eye. Laboratory biomarkers of cardiovascular dis-ease were evaluated before the first intravitreal injection of aflibercept and at 7 and 30 days after aflibercept administration. More precisely, we evaluated the levels of homocysteine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and C-reactive protein. Results: There was not any statistically significant change in the levels of the evaluated parameters up to one month after the first intravitreal injection of aflibercept. Conclusion: According to our study, the administration of a single dose of aflibercept in eyes with neovascular age-related macular degeneration does not seem to affect the evaluated biomarkers that are related to cardiovascular disease. Objective: Systemic administration of anti-Vascular Endothelial Growth Factors (an-ti-VEGFs) has been associated with severe cardiovascular adverse events in oncologic patients. The purpose of this pilot study is to evaluate the short-term effect of a single intravitreal injection of aflibercept on biomarkers related to increased risk of cardiovascular disease. Patients and Methods: Forty-seven treatment na & iuml;ve patients with neovascular age-related macular degeneration in one eye were enrolled in the study. The patients underwent treatment with one in-travitreal injection of aflibercept in the affected eye. Laboratory biomarkers of cardiovascular dis-ease were evaluated before the first intravitreal injection of aflibercept and at 7 and 30 days after aflibercept administration. More precisely, we evaluated the levels of homocysteine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and C-reactive protein. Results: There was not any statistically significant change in the levels of the evaluated parameters up to one month after the first intravitreal injection of aflibercept. Conclusion: According to our study, the administration of a single dose of aflibercept in eyes with neovascular age-related macular degeneration does not seem to affect the evaluated biomarkers that are related to cardiovascular disease.
